Condition (MeSH)
Hyperlipidemia, Familial Combined
ClinicalTrials.gov lists 10 trials for Hyperlipidemia, Familial Combined or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
10 of the 10 trials are tagged with Hyperlipidemia, Familial Combined itself; the rest are tagged with a narrower condition beneath it.
When did Hyperlipidemia, Familial Combined trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2017 | 1 |
| 2014 | 1 |
| 2007 | 1 |
| 2006 | 1 |
| 2005 | 1 |
| 2004 | 1 |
| 2003 | 2 |
| 2001 | 1 |
| 1993 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hyperlipidemia, Familial Combined trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 6 |
How many Hyperlipidemia, Familial Combined trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 8 |
| Withdrawn | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hyperlipidemia, Familial Combined trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Daiichi Sankyo | 1 |
| Kuhnil Pharmaceutical Co., Ltd. | 1 |
Which drugs are being tested for Hyperlipidemia, Familial Combined? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| ATORVASTATIN | 1 |
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Omega-3-acids ethylesters 90 4g | 1 |
| OGTT | 1 |
| PCSK9 Inhibitor [EPC] | 1 |
| colesevelam HCl tablets and fenofibrate tablets | 1 |
| Standard Lipid-Lowering Therapy | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Hyperlipidemia, Familial Combined? (55)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. | JAMA | 2019 | Yes |
| Glucose-dependent leukocyte activation in patients with type 2 diabetes mellitus, familial combined hyperlipidemia and healthy controls. | Metabolism: clinical and experimental | 2015 | Yes |
| Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales. | Atherosclerosis | 2015 | Yes |
| Serum lipid responses to weight loss differ between overweight adults with familial hypercholesterolemia and those with familial combined hyperlipidemia. | The Journal of nutrition | 2014 | Yes |
| Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia. | The American journal of cardiology | 2012 | Yes |
Showing 5 of 55 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.